Last quarter (Q4 2024), Immunovant's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Immunovant's net income was $-75.32M. See Immunovant’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
Total Revenue	-	-	-	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 593.45M	$ 282.71M	$ 218.28M	$ 156.03M	$ 108.12M	$ 66.08M
Operating Income	$ -285.42M	$ -282.71M	$ -218.28M	$ -156.03M	$ -108.12M	$ -66.08M
Net Non Operating Interest Income Expense	$ 16.02M	$ 24.95M	$ 7.58M	-	$ 0.00	$ -625.00K
Other Income Expense	$ 1.75M	$ 1.01M	$ 253.00K	$ 781.00K	$ 328.00K	$ 412.00K
Pretax Income	$ -267.67M	$ -258.77M	$ -210.95M	$ -156.81M	$ -107.79M	$ -66.29M
Tax Provision	$ -316.00K	$ 567.00K	$ 9.00K	$ -84.00K	$ -358.00K	$ 97.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -267.35M	$ -259.34M	$ -210.96M	$ -156.73M	$ -107.43M	$ -66.39M
Basic EPS	$ -2.00	$ -1.88	$ -1.71	$ -1.43	$ -1.22	$ -1.54
Diluted EPS	$ -2.00	$ -1.88	$ -1.71	$ -1.43	$ -1.22	$ -1.54
Basic Average Shares	$ 530.95M	$ 138.10M	$ 123.08M	$ 109.68M	$ 87.76M	$ 43.20M
Diluted Average Shares	$ 530.95M	$ 138.10M	$ 123.08M	$ 109.68M	$ 87.76M	$ 43.20M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 593.45M	$ 282.71M	$ 218.28M	$ 156.03M	$ 108.12M	$ 66.08M
Net Income From Continuing And Discontinued Operation	$ -267.35M	$ -259.34M	$ -210.96M	$ -156.73M	$ -107.43M	$ -66.39M
Normalized Income	$ -179.26M	$ -204.43M	$ -166.65M	-	$ -107.43M	$ -66.39M
Interest Expense	-	-	-	-	$ 0.00	$ 625.00K
EBIT	$ -283.68M	$ -283.72M	$ -218.53M	$ -156.81M	$ -107.79M	$ -65.67M
EBITDA	$ -282.33M	$ -282.36M	$ -217.21M	$ -155.58M	$ -107.72M	$ -65.64M

Currency in USD

Immunovant Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing